These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

474 related items for PubMed ID: 2553254

  • 1. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
    Holm C, Covey JM, Kerrigan D, Pommier Y.
    Cancer Res; 1989 Nov 15; 49(22):6365-8. PubMed ID: 2553254
    [Abstract] [Full Text] [Related]

  • 2. Sister chromatid exchanges, chromosomal aberrations, and cytotoxicity produced by antitumor topoisomerase II inhibitors in sensitive (DC3F) and resistant (DC3F/9-OHE) Chinese hamster cells.
    Pommier Y, Kerrigan D, Covey JM, Kao-Shan CS, Whang-Peng J.
    Cancer Res; 1988 Feb 01; 48(3):512-6. PubMed ID: 2825977
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin.
    Hsiang YH, Lihou MG, Liu LF.
    Cancer Res; 1989 Sep 15; 49(18):5077-82. PubMed ID: 2548710
    [Abstract] [Full Text] [Related]

  • 6. Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors.
    Pommier Y, Kerrigan D, Schwartz RE, Swack JA, McCurdy A.
    Cancer Res; 1986 Jun 15; 46(6):3075-81. PubMed ID: 3009009
    [Abstract] [Full Text] [Related]

  • 7. Topoisomerase II-dependent and -independent mechanisms of etoposide resistance in Chinese hamster cell lines.
    Spiridonidis CA, Chatterjee S, Petzold SJ, Berger NA.
    Cancer Res; 1989 Feb 01; 49(3):644-50. PubMed ID: 2535964
    [Abstract] [Full Text] [Related]

  • 8. Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture.
    Tanizawa A, Pommier Y.
    Cancer Res; 1992 Apr 01; 52(7):1848-54. PubMed ID: 1312902
    [Abstract] [Full Text] [Related]

  • 9. Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
    Beck WT, Danks MK.
    Semin Cancer Biol; 1991 Aug 01; 2(4):235-44. PubMed ID: 1655118
    [Abstract] [Full Text] [Related]

  • 10. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M, Wessel I, Jensen LH, Holm B, Oliveri RS, Kenwrick S, Creighton AM, Nitiss JL, Jensen PB.
    Cancer Res; 1998 Apr 01; 58(7):1460-8. PubMed ID: 9537249
    [Abstract] [Full Text] [Related]

  • 11. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K, Petersen BO, Falck J, Helin K, Jensen PB, Sehested M.
    Clin Cancer Res; 2000 Apr 01; 6(4):1488-97. PubMed ID: 10778981
    [Abstract] [Full Text] [Related]

  • 12. Reduced formation of protein-associated DNA strand breaks in Chinese hamster cells resistant to topoisomerase II inhibitors.
    Pommier Y, Schwartz RE, Zwelling LA, Kerrigan D, Mattern MR, Charcosset JY, Jacquemin-Sablon A, Kohn KW.
    Cancer Res; 1986 Feb 01; 46(2):611-6. PubMed ID: 3000581
    [Abstract] [Full Text] [Related]

  • 13. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I.
    Gupta RS, Gupta R, Eng B, Lock RB, Ross WE, Hertzberg RP, Caranfa MJ, Johnson RK.
    Cancer Res; 1988 Nov 15; 48(22):6404-10. PubMed ID: 2846151
    [Abstract] [Full Text] [Related]

  • 14. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.
    Cheng MF, Chatterjee S, Berger NA.
    Oncol Res; 1994 Nov 15; 6(6):269-79. PubMed ID: 7865902
    [Abstract] [Full Text] [Related]

  • 15. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
    Rene B, Fosse P, Khelifa T, Jacquemin-Sablon A, Bailly C.
    Mol Pharmacol; 1996 Feb 15; 49(2):343-50. PubMed ID: 8632768
    [Abstract] [Full Text] [Related]

  • 16. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
    Bowman KJ, Newell DR, Calvert AH, Curtin NJ.
    Br J Cancer; 2001 Jan 05; 84(1):106-12. PubMed ID: 11139322
    [Abstract] [Full Text] [Related]

  • 17. The effect of two topoisomerase inhibitors on low-dose hypersensitivity and increased radioresistance in Chinese hamster V79 cells.
    Skov K, Zhou H, Marples B.
    Radiat Res; 1994 Apr 05; 138(1 Suppl):S117-20. PubMed ID: 8146313
    [Abstract] [Full Text] [Related]

  • 18. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons.
    D'Arpa P, Beardmore C, Liu LF.
    Cancer Res; 1990 Nov 01; 50(21):6919-24. PubMed ID: 1698546
    [Abstract] [Full Text] [Related]

  • 19. [Poisons of DNA topoisomerases I and II].
    Charcosset JY, Soues S, Laval F.
    Bull Cancer; 1993 Nov 01; 80(11):923-54. PubMed ID: 8081034
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.